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background
 
Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal
women with primary, estrogen-receptor–positive breast cancer. Despite this treatment,
however, some patients have a relapse.
 
methods
 
We conducted a double-blind, randomized trial to test whether, after two to three years
of tamoxifen therapy, switching to exemestane was more effective than continuing ta-
moxifen therapy for the remainder of the five years of treatment. The primary end point
was disease-free survival.
 
results
 
Of the 4742 patients enrolled, 2362 were randomly assigned to switch to exemestane,
and 2380 to continue to receive tamoxifen. After a median follow-up of 30.6 months,
449 first events (local or metastatic recurrence, contralateral breast cancer, or death)
were reported — 183 in the exemestane group and 266 in the tamoxifen group. The un-
adjusted hazard ratio in the exemestane group as compared with the tamoxifen group
was 0.68 (95 percent confidence interval, 0.56 to 0.82; P<0.001 by the log-rank test),
representing a 32 percent reduction in risk and corresponding to an absolute benefit in
terms of disease-free survival of 4.7 percent (95 percent confidence interval, 2.6 to 6.8)
at three years after randomization. Overall survival was not significantly different in the
two groups, with 93 deaths occurring in the exemestane group and 106 in the tamoxifen
group. Severe toxic effects of exemestane were rare. Contralateral breast cancer oc-
curred in 20 patients in the tamoxifen group and 9 in the exemestane group (P=0.04).
 
conclusions
 
Exemestane therapy after two to three years of tamoxifen therapy significantly improved
disease-free survival as compared with the standard five years of tamoxifen treatment.
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reast cancer is estrogen-depen-
 
dent in many cases, and reducing the estro-
gen levels by means of ovariectomy can
cause regression of established disease,
 
1
 
 especially
if the tumor is rich in estrogen receptors.
 
2
 
 The selec-
tive estrogen-receptor modulator tamoxifen blocks
the action of estrogen by binding to one of the acti-
vating regions of the estrogen receptor.
 
3,4
 
 When giv-
en to women with estrogen-receptor–positive breast
cancer for five years after surgery, tamoxifen reduces
the risk of recurrence by 47 percent and the risk of
death by 26 percent.
 
5
 
 The risk–benefit ratio of us-
ing tamoxifen for longer than five years remains
unclear,
 
6,7
 
 and trials addressing this question are
ongoing. International guidelines recommend that
patients should not receive adjuvant tamoxifen ther-
apy for more than five years outside the context of
a clinical trial.
 
8
 
Alternative endocrine therapy is often effective
after disease has relapsed despite tamoxifen treat-
ment, since at that point, estrogen receptors are still
present in most patients.
 
9
 
 Several trials have con-
firmed the superiority of aromatase inhibitors over
progestins in this setting.
 
10,11
 
 Aromatase is an en-
zyme that catalyzes the conversion of androgens to
estrogens. There are two classes of third-generation
oral aromatase inhibitors: irreversible steroidal in-
activators, exemplified by exemestane,
 
12,13
 
 and re-
versible nonsteroidal inhibitors, such as anastro-
zole and letrozole.
 
14
 
Exemestane inhibits aromatization in vivo by
about 98 percent.
 
15
 
 It is superior to megestrol ace-
tate with respect to time to progression in advanced
breast cancer
 
14
 
 and has antitumor effects in patients
who have no response to third-generation nonste-
roidal aromatase inhibitors.
 
16
 
 Preliminary results
show that exemestane is superior to tamoxifen as
first-line therapy for metastatic disease.
 
17
 
 Theo-
retically, exemestane should not cause endometri-
al thickening or endometrial cancer, which are oc-
casionally observed after tamoxifen therapy.
 
18
 
The Intergroup Exemestane Study (IES) was de-
signed to investigate whether exemestane, when
given to postmenopausal women who remained
free of recurrence after receiving adjuvant tamoxifen
therapy for two to three years for primary breast can-
cer, could prolong disease-free survival, as com-
pared with continued tamoxifen therapy. Here we
report the results of the second planned interim
analysis, which we are releasing in accordance with
the recommendation of the independent data and
safety monitoring committee.
 
study design
 
Our study is an international, intergroup, phase 3,
randomized, double-blind trial comparing the effi-
cacy and safety of continued adjuvant tamoxifen
therapy with the efficacy and safety of exemestane
therapy in postmenopausal women with primary
breast cancer who remain free of disease after re-
ceiving adjuvant tamoxifen therapy for two to three
years. Women were randomly assigned to receive
oral exemestane (25 mg) or tamoxifen (20 mg) dai-
ly in order to complete a total of five years of adju-
vant endocrine treatment (Fig. 1). Randomization
was performed with the use of permuted blocks
and was stratified according to center.
The primary end point was disease-free survival,
defined by the time from randomization to recur-
rence of breast cancer at any site, diagnosis of a sec-
ond primary breast cancer, or death from any cause.
Secondary end points included overall survival, the
incidence of contralateral breast cancer, and long-
term tolerability. For consistency and comparability
with other reported trials,
 
19
 
 we also report breast-
cancer–free survival, with censoring of deaths that
occurred without a recurrence of breast cancer or a
diagnosis of contralateral breast cancer. Results
from substudies assessing the quality of life, uterine
thickness, bone metabolism, and bone mineral den-
sity will be reported separately.
The study was coordinated by the International
Collaborative Cancer Group (ICCG), Imperial Col-
lege London, and conducted under the auspices of
the Breast International Group (BIG). The trial was
governed by a steering committee comprising rep-
resentatives from the ICCG, participating coopera-
tive groups, BIG, and the pharmaceutical-industry
sponsor. Data for each cooperative group were col-
lected by the group’s data center and collated cen-
trally by the ICCG Data Center. Central review and
querying and analysis of data were undertaken by
the ICCG Data Center in collaboration with the In-
stitute of Cancer Research, where the independent
statisticians were based. The sponsor had no access
to the trial data base or interim analyses. The study
was overseen by a data and safety  monitoring com-
mittee that was independent of the ICCG Data Cen-
ter, the steering committee, and the sponsor.
The institutional review board at each partici-
pating institution approved the study protocol, and
all patients gave written informed consent. Ran-
domization was performed by the data center for
b methods
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each cooperative group or through the ICCG Data
Center.
 
eligibility criteria
 
Patients were eligible if they had histologically
confirmed, completely resected unilateral invasive
breast carcinoma that was positive for estrogen re-
ceptors (as determined by means of standard immu-
nostaining procedures) or that was of unknown re-
ceptor status. Patients were postmenopausal (55
years of age or older with amenorrhea for more
than two years, or amenorrhea for more than one
year at the time of diagnosis) and had received ad-
juvant tamoxifen therapy for at least two years but
not more than three years and one month. Most pa-
tients (95 percent) received tamoxifen at a dose of
20 mg daily, but patients who received 30 mg daily
were eligible (and continued to receive the same
dose if they were assigned to the tamoxifen group).
Patients were required to have adequate hematolog-
ic, renal, and liver function at the time of random-
ization (defined as a normal blood count, a serum
creatinine concentration less than 1.5 times the up-
per limit of normal, and a serum alanine amino-
transferase concentration less than 2.5 times the up-
per limit of normal).
The criteria for exclusion included the presence
of a tumor with known negative estrogen-receptor
status; evidence of local relapse or a distant metas-
tasis since the time of diagnosis; a clinically signif-
icant skeletal, cardiac, or endocrine disorder; and
the use of hormone-replacement therapy within four
weeks before randomization. Patients were also ex-
cluded if they had clinical evidence of severe osteo-
porosis or a history of a previous neoplasm other
than carcinoma in situ of the cervix or basal-cell skin
carcinoma or if they were taking concomitant anti-
coagulant agents, a selective estrogen-receptor
 
Figure 1. Trial Schema. 
 
The percentage of patients who continue to receive treatment represents the percentage who are not known to have discon-
tinued their randomized treatment and who began initial tamoxifen therapy less than five years before December 31, 2003.
Diagnosis of breast cancer and
treatment for primary disease
2–3 yr of tamoxifen therapy
Randomization
2–3 Yr of tamoxifen therapy
n=2362
2–3 Yr of exemestane therapy
n=2380
266 First events
8.6% of patients continue
to receive treatment
183 First events 
8.4% of patients continue
to receive treatment
Yr after
randomization
0
2–3
Yr after
start of
tamoxifen
therapy
0
2–3
5
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modulator other than tamoxifen, or any other form
of hormonal therapy.
The protocol required adequate treatment of pri-
mary disease, including postoperative radiotherapy
in patients who had been treated with breast-pre-
serving surgery. Neoadjuvant chemotherapy was
permitted according to a consistent policy within
each center. Patients were required to have started
chemotherapy within three months after diagnosis
and to have begun receiving tamoxifen and radio-
therapy within three months after the completion
of chemotherapy.
 
follow-up procedures
 
Symptoms, side effects, findings on clinical exam-
ination, and the level of compliance with treatment
were recorded at three-month intervals during the
first year after randomization, every six months dur-
ing the second and third years, and annually there-
after. Hematologic and biochemical analyses and
mammography (if the local procedure permitted)
were performed annually.
 
statistical analysis
 
Enrollment of 4400 patients was required in order
to detect an absolute difference of 3.6 percent in
disease-free survival three years after randomiza-
tion (with 88 percent power and a two-sided level
of significance of 4.3 percent after adjustment for
interim analyses). The a priori expectation was that
the principal analysis would be conducted after 716
end-point events had occurred. Three interim effi-
cacy analyses were to be conducted, with the use of
O’Brien–Fleming stopping boundaries, after one
quarter, one half, and three quarters of the planned
total number of events. Emerging trial data and in-
terim analyses were reviewed by the independent
data and safety monitoring committee, whose terms
of reference dictated that their decisions be guided
(but not mandated) by the above stopping rules.
Analyses were performed according to the in-
tention-to-treat principle and included all patients
who underwent randomization. All data were cen-
sored on June 30, 2003, but the snapshot of data
used for the analysis of efficacy was updated to in-
clude all data received by the ICCG Data Center
through December 31, 2003. Log-rank tests were
used to compare the two groups. Two-sided P values
and 95 percent confidence intervals are reported.
Cox proportional-hazards regression was used to
adjust for prespecified prognostic factors.
 
20
 
 Hazard
ratios of less than 1.0 favor exemestane. Kaplan–
Meier time-to-event curves are presented. The
groups were compared in terms of the incidence of
adverse effects with the use of chi-square tests. Be-
cause of the early release of the efficacy results, data
on adverse events are provisional; the validation pro-
cess is ongoing. Here, we emphasize the adverse ef-
fects for which there is a difference between groups
with a P value of 0.01 or less.
 
study population
 
We recruited 4742 women from 37 countries and
20 cooperative groups between February 1998 and
February 2003. Recruitment continued beyond the
target enrollment of 4400 in order to complete ac-
crual to the substudies on the effects on bone and
quality of life. The median follow-up was 30.6
months (interquartile range, 23.9 to 36.6). The two
groups were balanced with regard to base-line char-
acteristics (Table 1). A total of 192 patients were sub-
sequently found to be ineligible (16 because of pre-
vious breast cancers, 31 because of previous other
cancers, 74 because they had undergone breast-
conserving surgery but had not received radiother-
apy, 25 because they were of uncertain menopausal
status, 24 because they had known estrogen-recep-
tor–negative tumors, 8 because they had used hor-
mone-replacement therapy within four weeks be-
fore randomization, and 14 for other reasons); these
patients are included in all analyses on an intention-
to-treat basis.
 
efficacy
 
The second interim analysis, which was triggered
by the reporting of 358 events, was presented to the
data and safety monitoring committee on Decem-
ber 2, 2003, and included all data that had been re-
ceived relating to events and follow-up through
June 30, 2003. At that meeting, the committee
recommended that key efficacy data be released,
because the O’Brien–Fleming stopping boundary
(P=0.004) had been exceeded. The steering com-
mittee agreed to the release at a meeting on Decem-
ber 3, 2003. This report constitutes a refined analysis
of that presented to the data and safety monitoring
committee.
A total of 449 first events were reported: 183 in
the exemestane group and 266 in the tamoxifen
group (Table 2). The unadjusted hazard ratio in the
exemestane group as compared with the tamoxifen
group was 0.68 (95 percent confidence interval, 0.56
results
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* Plus–minus values are means ±SD. Patients with missing data had no value reported for a given variable; for patients in 
the “unknown” category, data were reported as unknown.
† Data for positive and negative estrogen-receptor status include retrospectively ascertained status for some patients 
 
whose status was unknown at randomization.
 
Table 1. Base-Line Characteristics of the Patients and Tumors and Primary Treatment.*
Variable Exemestane (N=2362) Tamoxifen (N=2380)
 
Demographic characteristics
Age — yr 64.3±8.1 64.2±8.2
White race — no. (%) 2308 (97.7) 2325 (97.7)
Nodal status — no. (%)
Negative 1211 (51.3) 1211 (50.9)
1–3 Positive nodes 715 (30.3) 706 (29.7)
≥4 Positive nodes 321 (13.6) 330 (13.9)
Positive, but no. of nodes missing 5 (0.2) 9 (0.4)
Unknown 84 (3.6) 96 (4.0)
Missing data 26 (1.1) 28 (1.2)
Histologic type — no. (%)
Infiltrating ductal 1814 (76.8) 1871 (78.6)
Infiltrating lobular 346 (14.6) 327 (13.7)
Other 172 (7.3) 156 (6.6)
Unknown 3 (0.1) 1 (<0.1)
Missing data 27 (1.1) 25 (1.1)
Estrogen-receptor status — no. (%)†
Positive 1917 (81.2) 1936 (81.3)
Progesterone-receptor positive 1312 (55.6) 1307 (54.9)
Progesterone-receptor negative 351 (14.9) 384 (16.1)
Progesterone-receptor status unknown or missing 254 (10.8) 245 (10.3)
Negative 26 (1.1) 33 (1.4)
Unknown 398 (16.9) 392 (16.5)
Missing data 21 (0.9) 19 (0.8)
Progesterone-receptor status — no. (%)
Positive 1320 (55.9) 1313 (55.2)
Negative 360 (15.2) 395 (16.6)
Unknown 659 (27.9) 653 (27.4)
Missing data 23 (1.0) 19 (0.8)
Type of surgery — no. (%)
Mastectomy 1222 (51.7) 1235 (51.9)
Breast-conserving 1116 (47.2) 1123 (47.2)
Unknown 3 (0.1) 2 (0.1)
Missing data 21 (0.9) 20 (0.8)
Previous chemotherapy — no. (%)
Yes 766 (32.4) 765 (32.1)
No 1575 (66.7) 1596 (67.1)
Missing data 21 (0.9) 19 (0.8)
Previous hormone-replacement therapy — no. (%)
Yes 567 (24.0) 557 (23.4)
No 1723 (72.9) 1747 (73.4)
Unknown 51 (2.2) 54 (2.3)
Missing data 21 (0.9) 22 (0.9)
Duration of tamoxifen therapy at randomization — yr
Median 2.4 2.4
Interquartile range 2.1–2.7 2.1–2.7
Tamoxifen dose — no. (%)
20 mg 2243 (95.0) 2270 (95.4)
30 mg 77 (3.3) 76 (3.2)
Missing data 42 (1.8) 34 (1.4)
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to 0.82; P=0.00005 by the log-rank test), which cor-
responds to an absolute benefit of 4.7 percent (95
percent confidence interval, 2.6 to 6.8) at three years
(Fig. 2). Disease-free survival three years after ran-
domization was 91.5 percent (95 percent confidence
interval, 90.0 to 92.7) in the exemestane group and
86.8 percent (95 percent confidence interval, 85.1
to 88.3) in the tamoxifen group. In a subsidiary
analysis of breast-cancer–free survival in which
deaths of patients who did not have a recurrence or
contralateral breast cancer were censored, the haz-
ard ratio was 0.63 (95 percent confidence interval,
0.51 to 0.77; P=0.00001; 144 events in the exemes-
tane group vs. 227 in the tamoxifen group). Survival
free of distant disease was also better in the exemes-
tane group (hazard ratio, 0.66; 95 percent confi-
dence interval, 0.52 to 0.83; P=0.0004). A total of
199 patients have died (93 in the exemestane group
and 106 in the tamoxifen group). There is no statis-
tically significant difference in overall survival at this
stage (hazard ratio, 0.88; 95 percent confidence in-
terval, 0.67 to 1.16; P=0.37) (Fig. 2). The causes of
death are listed in Table 2. Exemestane significantly
reduced the risk of contralateral breast cancer (haz-
ard ratio, 0.44; 95 percent confidence interval, 0.20
to 0.98; P=0.04).
 
* Data for distant recurrence and primary cancer in the contralateral breast include patients who also reported a local re-
lapse. One patient in the exemestane group died of breast cancer after contralateral breast cancer had been reported and 
 
is also included in the analysis of distant-disease–free survival.
 
Table 2. End-Point Events.
Variable
Exemestane Group
(N=2362)
Tamoxifen Group
(N=2380)
All Patients
(N=4742)
 
no. of patients
 
Events included in analysis of disease-free survival*
Local recurrence only 21 33 54
Distant recurrence 114 174 288
Primary cancer in contralateral breast 9 20 29
Intercurrent death (without recurrence) 39 39 78
Recurrence, contralateral breast cancer, or intercurrent death 183 266 449
Death
Any cause 93 106 199
Breast-cancer–related 54 67 121
Intercurrent (without recurrence) 39 39 78
Vascular causes 12 6 18
Cardiac causes 10 8 18
Other cancer-related 6 10 16
Thrombotic causes 1 1 2
Pulmonary causes 0 1 1
Other causes 6 7 13
Unknown causes or missing data 4 6 10
Second primary non-breast cancer 27 53 80
Lung 4 12 16
Gastrointestinal 7 10 17
Endometrial 5 11 16
Other gynecologic 3 3 6
Genitourinary 3 4 7
Melanoma 1 5 6
Lymphoreticular 2 3 5
Other 2 5 7
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Adjusting for the prespecified prognostic fac-
tors did not affect the hazard ratios (Table 3), and
there was no evidence of heterogeneity among
subgroups defined according to estrogen-recep-
tor status, combined estrogen-receptor and pro-
gesterone-receptor status, number of positive
nodes, receipt or type of previous chemotherapy,
or use at any time of hormone-replacement thera-
py (Fig. 3).
 
adverse effects and safety
 
Exemestane was associated with a higher incidence
of arthralgia and diarrhea than tamoxifen, but gyne-
cologic symptoms, vaginal bleeding, and muscle
 
Figure 2. Kaplan–Meier Estimates of Disease-free Survival (Panel A) and Overall Survival (Panel B).
 
The hazard ratios are for the exemestane group as compared with the tamoxifen group. P values were determined by the 
log-rank test. An additional six patients in the exemestane group and four patients in the tamoxifen group had a recur-
rence or a second primary cancer in the contralateral breast or died more than four years after randomization (Panel A); 
an additional four patients in the exemestane group and two patients in the tamoxifen group died more than four years 
after randomization (Panel B).
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cramps were more common with tamoxifen (Table
4). Thromboembolic events were recorded more
frequently in the tamoxifen group than in the exe-
mestane group (55 patients [2.4 percent] vs. 30 pa-
tients [1.3 percent], P=0.007). There was also a sug-
gestion of an increased incidence of osteoporosis
and visual disturbances associated with exemestane.
Fractures were reported more frequently in the ex-
emestane group than in the tamoxifen group, al-
though the difference was not statistically signifi-
cant (72 patients [3.1 percent] vs. 53 patients [2.3
percent], P=0.08). More patients in the tamoxifen
group than in the exemestane group had a second
primary non-breast cancer that occurred before a
distant relapse (53 patients [2.2 percent] vs. 27 pa-
tients [1.1 percent]; hazard ratio, 0.51; 95 percent
confidence interval, 0.32 to 0.80; P=0.003) (Table
2). Specifically, cancer of the endometrium, lung
cancer, and melanoma developed in fewer patients
in the exemestane group than in the tamoxifen
group, although these individual differences were
not statistically significant.
 
treatment compliance
 
Randomly assigned treatment was stopped early in
667 patients (365 in the exemestane group and 302
in the tamoxifen group; 14.1 percent of the total
study population) for reasons other than relapse or
death, after a median total duration of treatment of
36.1 months (from the initiation of tamoxifen ther-
apy). A total of 138 patients in the exemestane group
and 121 in the tamoxifen group discontinued ther-
apy because of adverse events, and another 164
patients in the exemestane group and 116 in the ta-
moxifen group refused to continue therapy. An ad-
ditional 63 patients in the exemestane group and
65 in the tamoxifen group have discontinued their
randomly assigned treatment for other reasons,
including protocol violations, or have been lost to
follow-up. On the basis of the time since random-
ization, 9 percent of patients are likely to be still re-
ceiving treatment.
We found that switching patients to adjuvant treat-
ment with exemestane after two to three years of ta-
moxifen therapy was associated with a statistically
and clinically significant improvement in disease-
free survival, which included a reduction in the in-
cidence of metastatic disease. This strategy also
reduced the risks of contralateral breast cancer, en-
dometrial cancer, and intriguingly, other primary
cancers. At the time of this report, the observed
number of deaths over the relatively short follow-up
period precludes the detection of a statistically sig-
nificant difference in overall survival.
The data and safety monitoring committee rec-
ommended the early release of results on the basis
of a planned interim analysis. More than 90 per-
cent of the patients will have completed their ran-
domly assigned treatment by the time this report is
published; thus, the trial should still be able to
achieve its long-term assessment of survival bene-
fit. There are several theoretical reasons to suggest
a benefit of sequential endocrine therapy involving
switching from tamoxifen to an aromatase inhibi-
tor after two to three years. First, many patients with
breast cancer have a relapse and die of metastatic
disease within five years after the initial diagnosis.
Second, in both patients with primary cancer and
those with metastatic disease, resistance occurs as
early as 12 to 18 months after the initiation of ta-
moxifen therapy. In some patients with resistant
disease, tamoxifen may act as an agonist, potential-
ly stimulating the division of breast-cancer cells.
Third, serious side effects of tamoxifen, including
thromboembolism and uterine carcinoma, can oc-
cur after prolonged use. Fourth, since tamoxifen can
decrease bone resorption,
 
21
 
 we reasoned that pre-
treatment with tamoxifen might lessen the effect of
any osteopenia caused by exemestane.
When we designed this study, there was consid-
erable uncertainty regarding the optimal duration
discussion
 
* A Cox model including estrogen-receptor status (either positive or negative, 
unknown or missing), nodal status (negative, 1 to 3 positive nodes, 4 or more 
positive nodes, or unknown or missing), chemotherapy (yes or no), and use of 
hormone-replacement therapy (yes, no, or unknown or missing) was used to 
estimate the adjusted hazard ratios. Forty patients with unknown chemother-
apy status were excluded from the analysis. CI denotes confidence interval. 
 
P values were determined by the log-rank test.
 
Table 3. Hazard Ratios in the Exemestane Group as Compared 
with the Tamoxifen Group.*
End Point Unadjusted Adjusted
 
Hazard Ratio
(95% CI) P Value
Hazard Ratio
(95% CI) P Value
Disease-free survival 0.68 (0.56–0.82) <0.001 0.67 (0.56–0.82) <0.001
Breast-cancer–free 
survival
0.63 (0.51–0.77) <0.001 0.62 (0.50–0.76) <0.001
Time to contralateral 
breast cancer
0.44 (0.20–0.98) 0.04 0.44 (0.20–0.98) 0.04
Overall survival 0.88 (0.67–1.16) 0.37 0.89 (0.67–1.17) 0.41
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of adjuvant tamoxifen therapy in patients with pri-
mary breast cancer. The 1990 overview by the Early
Breast Cancer Trialists’ Collaborative Group had
suggested that there was a likely benefit of continu-
ing tamoxifen therapy for five years.
 
22
 
 Randomized
trials directly comparing two years of tamoxifen
therapy with five years of tamoxifen therapy
 
23,24
 
confirmed that there was a relative risk reduction of
18 to 19 percent with the longer-term therapy. Thus,
although five years of tamoxifen treatment was the
identified standard, switching treatment after only
two to three years was postulated to offer patients
the bulk of the benefit of tamoxifen while minimiz-
ing the risk of long-term side effects.
Despite the promising results of the Anastrozole,
Tamoxifen Alone or in Combination Trialists’ Group
(ATAC) study, which showed that anastrozole was
superior to tamoxifen,
 
25
 
 five years of tamoxifen
therapy remains the widely recommended standard
for adjuvant treatment,
 
8
 
 although the Food and
Drug Administration recently approved anastrozole
monotherapy as an alternative. A study by Goss et
al.
 
19
 
 found that after five years of tamoxifen thera-
py, patients who received letrozole had a higher rate
of disease-free survival than those who received pla-
cebo. Our large, multicenter study challenges the
concept of five years of monotherapy with endocrine
agents after the surgical treatment of primary breast
cancer. Two smaller studies conducted by Italian re-
searchers have used sequential aminoglutethimide
after tamoxifen therapy in 308 patients
 
26
 
 and anas-
trozole after tamoxifen therapy in 426 patients.
 
27
 
Although they were underpowered, both trials sug-
gested that the sequence may be better than tamox-
ifen alone, supporting the results we present here.
The improvement in disease-free survival
achieved by switching from tamoxifen to exemes-
tane is consistent with the hypothesis that breast
cancer frequently becomes resistant to tamoxifen
within five years after treatment is initiated. The mo-
lecular mechanisms underlying such resistance are
unclear. Laboratory studies indicate that a reduction
in the antagonist properties of tamoxifen caused by
the up-regulation of tyrosine kinase receptors (in
 
Figure 3. Subgroup Analysis of Disease-free Survival.
 
The hazard ratio given for all patients was adjusted for estrogen-receptor status, nodal status, receipt or nonreceipt of chemotherapy, and use 
or nonuse of hormone-replacement therapy (P=0.00004). The size of the rectangles is proportional to the size of the subgroups.
Subgroup (no.)
0.4 0.6 0.8 1.0 1.2
Hazard Ratio (log scale)
Hazard Ratio
Favors
Exemestane
Favors
Tamoxifen
Progesterone-receptor–positive (2619)
Progesterone-receptor–negative (735)
Progesterone-receptor status 
unknown (499)
Estrogen-receptor status negative 
 or unknown (889)
Hormone-receptor status
Estrogen-receptor–positive (3853)
1–3 Positive nodes (1421)
≥4 Positive nodes (651)
Previous hormone-replacement therapy
Yes (1124)
No (3470)
Previous chemotherapy
All patients (4742)
Yes (1531)
No (3171)
Nodal status
Negative (2422)
0.64 (0.52–0.79)
0.66 (0.51–0.87)
0.58 (0.38–0.90)
0.67 (0.39–1.16)
0.85 (0.57–1.29)
0.68 (0.48–0.95)
0.71 (0.51–0.98)
0.58 (0.42–0.81)
0.63 (0.40–0.99)
0.69 (0.56–0.85)
0.69 (0.51–0.92)
0.67 (0.52–0.86)
0.67 (0.56–0.82)
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particular, HER2 and epidermal growth-factor re-
ceptors), downstream protein kinases (such as mi-
togen-activated protein kinase
 
28
 
 and protein kinase
B, or Akt
 
29
 
), or both may result in a significant in-
crease in the agonist activity of tamoxifen, as well
as increased sensitivity to estradiol. These effects
could explain the benefit that has been observed to
result from lowering the estradiol level through the
sequential use of an aromatase inhibitor.
 
9
 
Results in the subgroup with estrogen-receptor–
positive breast cancer were very similar to those
among all patients. According to an unplanned sub-
group analysis, exemestane seemed to be equally ef-
fective in both progesterone-receptor–positive and
progesterone-receptor–negative subgroups, as well
as in node-positive and node-negative subgroups,
contrary to the report suggesting that patients with
estrogen-receptor–positive and progesterone-recep-
tor–negative carcinomas may preferentially benefit
from anastrozole therapy.
 
30
 
The reduction in the incidence of contralateral
breast cancer in the exemestane group as compared
with the tamoxifen group (hazard ratio, 0.44; 95
percent confidence interval, 0.20 to 0.98; P=0.04)
suggests that preventive strategies involving the
prolonged use of tamoxifen monotherapy
 
31,32
 
 may
not be optimal. The nonsignificant decrease in the
rate of endometrial cancer is consistent with ex-
pectations, since tamoxifen therapy is a well-rec-
ognized risk factor for endometrial cancer.
 
33,34
 
The decreased incidence of other second primary
(non-breast) cancers is more difficult to explain.
 
* Data are given for adverse events whose incidence in the two groups differed by 1 percent or more, for which the difference between groups 
was significant at the 1 percent level, or whose incidence was at least 10 percent in either group. Grades are according to Common Toxicity Cri-
teria of the National Cancer Institute (version 1.0). Data on cardiovascular disease, gynecologic symptoms, osteoporosis, and arthralgia were 
available for 2309 patients in the exemestane group and 2332 patients in the tamoxifen group; data on the other adverse effects were available 
for 2305 and 2329 patients, respectively. Pain or aches, arthralgia, depression, diarrhea, and cramps were recorded in an “other” category; 
data are preliminary and may underestimate the true incidence. For graded adverse events, P values were determined by trend tests combin-
 
ing grades 3 and 4.
 
Table 4. Adverse Events.*
Type of Event Exemestane Group Tamoxifen Group P Value
 
Grade
1
Grade
2
Grade
3
Grade
4 Any Grade
Grade
1
Grade
2
Grade
3
Grade
4 Any Grade
 
number (percent)
 
Cardiovascular disease other than
myocardial infarction
984 (42.6) 913 (39.2) 0.016
Hot flashes 504 363 97 3 967 (42.0) 493 342 84 4 923 (39.6) 0.082
Pain or aches 392 305 61 8 766 (33.2) 383 242 55 4 684 (29.4) 0.001
Fatigue 336 178 31 0 545 (23.6) 352 157 36 2 547 (23.5) 0.776
Insomnia 269 143 37 0 449 (19.5) 234 140 31 1 406 (17.4) 0.151
Sweating 222 153 51 3 429 (18.6) 215 145 57 1 418 (17.9) 0.702
Headaches 272 129 26 1 428 (18.6) 243 116 17 2 378 (16.2) 0.035
Dizziness 206 73 9 0 288 (12.5) 192 74 13 0 279 (12.0) 0.904
Nausea 177 57 14 0 248 (10.8) 189 53 16 0 258 (11.1) 0.835
Visual disturbances 134 32 4 0 170 (7.4) 115 8 10 0 133 (5.7) 0.024
Osteoporosis 171 (7.4) 134 (5.7) 0.023
Gynecologic symptoms 135 (5.8) 211 (9.0) <0.001
Arthralgia 124 (5.4) 85 (3.6) 0.005
Depression 68 50 2 0 120 (5.2) 51 37 5 0 93 (4.0) 0.114
Diarrhea 63 28 8 1 100 (4.3) 37 16 1 0 54 (2.3) <0.001
Vaginal bleeding 49 33 11 0 93 (4.0) 73 50 5 1 129 (5.5) 0.087
Cramps 45 16 3 0 64 (2.8) 60 37 3 2 102 (4.4) 0.002
Thromboembolic disease
Including ungraded serious
adverse events
11 4 8 1 24 (1.0)
30 (1.3)
11 13 15 6 45 (1.9)
55 (2.4)
0.005
0.007
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Reports of associations between tamoxifen therapy
and cancer at other sites have been inconclusive,
 
34
 
and such associations were not substantiated by the
Early Breast Cancer Trialists’ Collaborative Group
study.
 
5
 
 Thus, it is not clear whether the observed dif-
ferences in the incidence of new primary cancers
represent increases in risks due to tamoxifen treat-
ment, a previously unreported protective effect of an
aromatase inactivator, or chance findings.
The rate of discontinuation of treatment was
slightly higher in the exemestane group than in the
tamoxifen group, perhaps reflecting differences
in the side-effect profiles of the two treatments
that may have been particularly evident to patients
switching from one treatment to another. The analy-
sis of adverse events indicated that there was a low-
er incidence of thromboembolic events among
women who switched to exemestane. There was a
slight but nonsignificant increase in the rate of os-
teoporosis and reported fractures in the exemes-
tane group as compared with the tamoxifen group.
Recent studies have shown that all third-generation
aromatase inhibitors or inactivators increase bone
resorption.
 
35,36
 
 The substudy of the IES on bone
mineral density aims to determine the degree of
bone mineral loss in patients who have been treat-
ed with tamoxifen and then switched to exemestane.
The increase in the rate of arthralgia in the exemes-
tane group is similar to that seen with other aroma-
tase inhibitors,
 
37
 
 and diarrhea has been reported
previously in patients receiving exemestane.
 
16
 
 Cho-
lesterol levels, which were reduced by tamoxifen
treatment,
 
38
 
 were found to be unaltered in another
study of exemestane
 
39
 
 but were not systematically
measured in the present study; we have not observed
a significantly increased incidence of myocardial
infarction (1.0 percent in the exemestane group vs.
0.4 percent in the tamoxifen group). 
Several issues still need to be clarified, including
the correct sequence of therapy, which we believe to
be an important factor in the success of this study
and that reported by Goss et al.,
 
19
 
 as well as the ef-
fect of aromatase inhibition on bone metabolism.
The answers to these questions will have to await
the results of ongoing and new studies. Our results
add to the evidence that the sequential use of aro-
matase inactivators and tamoxifen provides addi-
tional options for improving adjuvant endocrine
therapy for postmenopausal women with hormone-
responsive primary breast cancer. Our results indi-
cate that five years of tamoxifen monotherapy after
surgery may be suboptimal for postmenopausal pa-
tients with estrogen-receptor–positive breast cancer
and suggest that clinicians should consider switch-
ing patients to exemestane between two and three
years after the start of tamoxifen therapy.
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